Administration of thrombolytic therapy to 17,944 patients with acute myocardial infarction: The GISSI-3 database

被引:7
作者
Bobbio, M
Bergerone, S
Maggioni, AP
Malacrida, R
Franzosi, MG
Barlera, S
Tognoni, G
机构
[1] Univ Turin, Osped Molinette, Div Cardiol, I-10126 Turin, Italy
[2] Ist Ric Farmacol Mario Negri, Milan, Italy
[3] Med Cardiol Ospedalieri, Ctr Studi Assoc Nazl, Florence, Italy
[4] Osped Civico, Lugano, Switzerland
关键词
D O I
10.1016/S0002-8703(98)70320-5
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background There is growing interest in assessing therapy for acute myocardial infarction. Because thrombolysis was not a study therapy in the GISSI-3 trial, the decision about thrombolysis was left to the responsible physicians. We evaluated the data on thrombolytic therapy among patients with acute myocardial infarction enrolled in the GISSI-3 trial to study the relation between rate of prescription and the characteristics of patients and participating coronary care units. Methods Complete clinical data were available for 17,944 patients randomized between June 1991 and July 1993 from 200 coronary care units in Italy. Demographic and clinical information were obtained for each patient, and each coronary care unit was classified according to patient volume, level of technology, and wide geographic area in which it was located. A multivariate logistic regression was performed with administration of thrombolytic therapy as the dependent variable and previously defined clinical and structural variables as independent variables. Results The most important factor in administration of thrombolytic therapy was that less than 6 hours elapse from symptom onset to hospital admission (odds ratio [OR] 14.05; 95% confidence interval [Cl] 12.3 to 16.0). Next were location of coronary care unit in southern Italy (OR 1.81; 95% Cl 1.62 to 2.01), presence of ST elevation at entrance electrocardiogram ECG (OR 1.47; 95% Cl 1.35 to 1.61), absence of previous myocardial infarction (OR 1.35; 95% Cl 1.22 to 1.49), and presence of catheterization laboratory or cardiac surgery program or both in the same hospital (OR 1.24; 95% Cl 1.14 to 1.35). Coronary care units with high or low patient volume did not show different rates of administration of thrombolytic agents. Conclusions The GISSI-3 experience confirmed a high rate of prescription of thrombolytic therapy to patients admitted within 6 hours of symptom onset and those with ST-segment elevation on entrance electrocardiogram. It demonstrated that patients admitted to coronary care units with catheterization laboratories or cardiac programs or both have higher chances of receiving thrombolytic treatment than those admitted to hospitals without these capabilities.
引用
收藏
页码:443 / 448
页数:6
相关论文
共 27 条
[1]   THE WESTERN WASHINGTON MYOCARDIAL-INFARCTION REGISTRY AND EMERGENCY DEPARTMENT TISSUE PLASMINOGEN-ACTIVATOR TREATMENT TRIAL [J].
ALTHOUSE, R ;
MAYNARD, C ;
CERQUEIRA, MD ;
OLSUFKA, M ;
RITCHIE, JL ;
KENNEDY, JW .
AMERICAN JOURNAL OF CARDIOLOGY, 1990, 66 (19) :1298-1303
[2]  
[Anonymous], 1994, Circulation, V89, P1545
[3]  
[Anonymous], 1988, LANCET, V2, P349
[4]  
[Anonymous], 1986, LANCET, V1, P397
[5]   A COMPARISON OF RESULTS OF METAANALYSES OF RANDOMIZED CONTROL TRIALS AND RECOMMENDATIONS OF CLINICAL EXPERTS - TREATMENTS FOR MYOCARDIAL-INFARCTION [J].
ANTMAN, EM ;
LAU, J ;
KUPELNICK, B ;
MOSTELLER, F ;
CHALMERS, TC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (02) :240-248
[6]  
BERNSTEIN SJ, 1992, CORONARY ANGIOGRAPHY, P47
[7]   HIGH-TECHNOLOGY CARDIAC PROCEDURES - THE IMPACT OF SERVICE AVAILABILITY ON SERVICE USE IN NEW-YORK-STATE [J].
BLUSTEIN, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (03) :344-349
[8]  
COLLINS R, 1995, LANCET, V345, P669
[9]   OUTCOME OF PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION WHO ARE INELIGIBLE FOR THROMBOLYTIC THERAPY [J].
CRAGG, DR ;
FRIEDMAN, HZ ;
BONEMA, JD ;
JAIYESIMI, IA ;
RAMOS, RG ;
TIMMIS, GC ;
ONEILL, WW ;
SCHREIBER, TL .
ANNALS OF INTERNAL MEDICINE, 1991, 115 (03) :173-177
[10]  
DEVITA C, 1994, LANCET, V343, P1115